Ranbaxy Exits Pfizer's Suit Over Generic Rapamune

Law360, New York (February 6, 2012, 7:32 PM EST) -- Ranbaxy Laboratories Ltd. on Monday exited a patent infringement suit launched by Pfizer Inc. against it and Watson Pharmaceuticals Inc. in Delaware federal court in response to abbreviated new drug applications to introduce a generic version of the organ rejection drug Rapamune.

In a sealed order, U.S. District Judge Richard G. Andrews signed off on a joint stipulation of dismissal without prejudice, allowing the company and its subsidiaries Ranbaxy Pharmaceuticals Inc. and Ranbaxy Inc. to exit the suit with each side bearing its own attorneys' fees...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.